PURPOSE: Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT). We investigated whether VA use during RT for GB was associated with overall survival (OS). METHODS AND MATERIALS: Medical records of 544 adults with GB were retrospectively reviewed. Analyses were performed to determine the association of Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) class, seizure history, and concurrent temozolomide (TMZ) and AED use during RT with OS. RESULTS: Seizures before the end of RT were noted in 217 (40%) patients, and 403 (74%) were taking an AED during RT; 29 (7%) were taking VA. Median OS in patients taking VA was 16.9 months (vs 13.6 months taking another AED, P=.16). Among patients taking an AED during RT, OS was associated with VA (P=.047; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.27-1.07), and RTOG RPA class (P<.0001; HR, 1.49; 95% CI, 1.37-1.61). Of the 5 most common AEDs, only VA was associated with OS. Median OS of patients receiving VA and TMZ during RT was 23.9 months (vs 15.2 months for patients taking another AED, P=.26). When the analysis was restricted to patients who received concurrent TMZ, VA use was marginally associated with OS (P=.057; HR, 0.54; 95% CI, -0.09 to 1.17), independently of RTOG RPA class and seizure history. CONCLUSIONS: VA use during RT for GB was associated with improved OS, independently of RTOG RPA, seizure history, and concurrent TMZ use. Further studies of treatment that combines HDAC inhibitors and RT are warranted.
PURPOSE:Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT). We investigated whether VA use during RT for GB was associated with overall survival (OS). METHODS AND MATERIALS: Medical records of 544 adults with GB were retrospectively reviewed. Analyses were performed to determine the association of Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) class, seizure history, and concurrent temozolomide (TMZ) and AED use during RT with OS. RESULTS:Seizures before the end of RT were noted in 217 (40%) patients, and 403 (74%) were taking an AED during RT; 29 (7%) were taking VA. Median OS in patients taking VA was 16.9 months (vs 13.6 months taking another AED, P=.16). Among patients taking an AED during RT, OS was associated with VA (P=.047; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.27-1.07), and RTOG RPA class (P<.0001; HR, 1.49; 95% CI, 1.37-1.61). Of the 5 most common AEDs, only VA was associated with OS. Median OS of patients receiving VA and TMZ during RT was 23.9 months (vs 15.2 months for patients taking another AED, P=.26). When the analysis was restricted to patients who received concurrent TMZ, VA use was marginally associated with OS (P=.057; HR, 0.54; 95% CI, -0.09 to 1.17), independently of RTOG RPA class and seizure history. CONCLUSIONS:VA use during RT for GB was associated with improved OS, independently of RTOG RPA, seizure history, and concurrent TMZ use. Further studies of treatment that combines HDAC inhibitors and RT are warranted.
Authors: Anupama Munshi; John F Kurland; Takashi Nishikawa; Toshimitsu Tanaka; Marvette L Hobbs; Susan L Tucker; Sheikh Ismail; Craig Stevens; Raymond E Meyn Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531
Authors: Krista A Van Nifterik; Jaap Van den Berg; Ben J Slotman; M Vincent M Lafleur; Peter Sminia; Lukas J A Stalpers Journal: J Neurooncol Date: 2011-10-26 Impact factor: 4.130
Authors: Prakash Chinnaiyan; David Cerna; William E Burgan; Katie Beam; Eli S Williams; Kevin Camphausen; Philip J Tofilon Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Jeremy D Ruben; Michael Dally; Michael Bailey; Robin Smith; Catriona A McLean; Pasqual Fedele Journal: Int J Radiat Oncol Biol Phys Date: 2006-03-06 Impact factor: 7.038
Authors: Mèlanie S M van Breemen; R M Rijsman; M J B Taphoorn; R Walchenbach; H Zwinkels; Charles J Vecht Journal: J Neurol Date: 2009-05-12 Impact factor: 4.849
Authors: Philip Lee; Ben Murphy; Rickey Miller; Vivek Menon; Naren L Banik; Pierre Giglio; Scott M Lindhorst; Abhay K Varma; William A Vandergrift; Sunil J Patel; Arabinda Das Journal: Anticancer Res Date: 2015-02 Impact factor: 2.480
Authors: Abdel Nasser Hosein; Yi Chieh Lim; Bryan Day; Brett Stringer; Stephen Rose; Richard Head; Leah Cosgrove; Peter Sminia; Michael Fay; Jennifer H Martin Journal: J Neurooncol Date: 2015-02-04 Impact factor: 4.130